Mitchell Mah'moud, MD
Gastroenterology · Smithfield, NCNPI 1699769257
Payments from drug & device makers
Across 414 payments — averaging $1099.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$265K
- Gilead$38K
- Ipsen Biopharmaceuticals, Inc$36K
- Madrigal Pharmaceuticals$35K
- Boehringer Ingelheim International GmbH$34K
- Sanofi US Services Inc.$16K
- plus $30K from 22 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 112 | $265,357 |
| Gilead | 30 | $38,195 |
| Ipsen Biopharmaceuticals, Inc | 19 | $36,330 |
| Madrigal Pharmaceuticals | 43 | $34,500 |
| Boehringer Ingelheim International GmbH | 48 | $33,878 |
| Sanofi US Services Inc. | 1 | $16,495 |
| Shionogi Inc | 8 | $12,343 |
| Bristol Myers Squibb | 8 | $5,844 |
| AbbVie | 75 | $5,843 |
| Mirum Pharmaceuticals, Inc. | 1 | $1,625 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $1,530 |
| Dova Pharmaceuticals | 2 | $1,326 |
| UCB Biosciences Inc. | 1 | $520 |
| Pfizer | 24 | $479 |
| Ferring Pharmaceuticals Inc. | 4 | $189 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $157 |
| Novo Nordisk | 1 | $101 |
| Regeneron Healthcare Solutions, Inc. | 4 | $86 |
| Aimmune Therapeutics, Inc. | 4 | $82 |
| Nestle Healthcare Nutrition Inc. | 3 | $63 |
| Braintree Laboratories, Inc. | 3 | $61 |
| Sanofi | 2 | $50 |
| Merck | 3 | $41 |
| Ardelyx, Inc. | 2 | $31 |
| Orphalan Inc | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| QOL Medical, LLC | 1 | $17 |
How this compares
$455,202 in reported general payments places this provider in the 90th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Smithfield
- Evan DellonChapel Hill$11.2M
- Andrew MuirDurham$6.6M
- Manal AbdelmalekDurham$5.6M
- Robert ReindollarSalisbury$2.5M
- John PoulosFayetteville$2.1M
- Hans HerfarthChapel Hill$2M
- Herbert BonkovskyWinston Salem$1.7M
- Ikechukwu IbegbuJacksonville$1.5M
- Nicholas ShaheenChapel Hill$1.5M
- David LeimanDurham$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.